BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Novartis Europharm Ltd. submitted on 5 September 2006 an application for Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Rasilez,  through  the  centralised 
procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 23 February 2006.  
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data, non-clinical and clinical data based on 
applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain test(s) 
or study(ies) 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  the  CHMP  on  3  June  2004.  The  Scientific  Advice 
pertained to non-clinical and clinical aspects of the dossier.  
Licensing status: 
A new application was filed in the following countries: USA, Canada. 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:   Giuseppe Nisticó 
Co-Rapporteur: János Borvendég 
CHMP Peer reviewers: Alar Irs, Karl Broich 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 5 September 2006. 
The procedure started on 27 September 2006.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  
11 December 2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP 
members on 8 December 2006.  
During  the  meeting  on  22-24  January  2007,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 25 January 2007. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  
15 March 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 27 April 2007. 
During  the  CHMP  meeting  on  21-24  May  2007,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding Issues to all CHMP members on 9 June 2007. 
During the meeting on 18-21 June 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Rasilez  on  21  June  2007.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 15 June 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 22 August 2007. 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
